<DOC>
	<DOCNO>NCT01414283</DOCNO>
	<brief_summary>Prostate-specific Membrane Antigen Antibody-Drug Conjugate ( PSMA ADC ) 1301 open-label , dose-escalation phase 1 study PSMA ADC administer IV subject progressive , castration-resistant , metastatic prostate cancer progress prior taxane therapy . For subject , PSMA ADC administer four repeating cycle .</brief_summary>
	<brief_title>Prostate-specific Membrane Antigen Antibody-Drug Conjugate Subjects With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . A diagnosis progressive , castrationresistant , metastatic prostate cancer . 2 . Prior chemotherapy regimen , one contain taxane . 3 . Eastern Cooperative Oncology Group status 0 1 1 . Clinically significant cardiac disease severe debilitation pulmonary disease 2 . Evidence active infection require ongoing antibiotic therapy 3 . Any prior treatment therapy target PSMA 4 . History drug and/or alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>